New combo therapy aims to keep lung cancer from returning after surgery

NCT ID NCT06624059

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study looks at whether adding the targeted drug alectinib to standard chemotherapy is safe for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after they have had surgery to remove the tumor. The trial involves 11 participants with stage II to IIIB disease. The main goal is to check for side effects, not to prove the treatment works long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

    Perugia, Umbria, 06156, Italy

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Guangdong General Hospital

    Guangzhou, 510000, China

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000, Brazil

  • Jinhua municipal central hospital

    Jinhua, China

  • RedSalud Vitacura

    Santiago, Chile

  • Royal North Shore Hospital

    St Leonards, New South Wales, 2065, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • The third people's hospital of Chengdu

    Chengdu, China

  • Yunnan Cancer Hospital

    Kunming, 650118, China

Conditions

Explore the condition pages connected to this study.